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61. INTRODUCTION
Alzheimer’s disease (AD) is the most common form of senile dementia, affecting more 
than 20 million people worldwide. In Hungary the number of AD patients may be more than 
one thousand. With increasing life expectancy, this number will inevitably rise rapidly in the 
future, not only in the western world, but also in Hungary. Statistical data demonstrate that 
AD is the fourth leading cause of death after heart disease, cancer and stroke. It is the most 
common cause of dementia in the elderly, characteristically involving a progressive loss of 
cognition and changes in personality. The usual presenting symptom is a memory loss, which 
is often associated with language, visuospatial and attention problems.
Several theories have been put forward to account for the development of 
neuropathological changes in the AD brain. The real aetiopathological factor, however, 
remains a mystery. The results of the wide-ranging scientific research on AD prove the 
complexity of this disease. Various lines of evidence indicate that a number of factors may 
play a role in the development of the disease.
So many hypotheses have been put forward to explain the aetiology of AD, that the 
situation is far from clear. Our attention turned first towards the amyloid cascade 
hypothesis2*. It has long been known that one of most important neuropathological changes in 
AD is the accumulation of Aß-positive senile plaques (SPs) in the various areas of the central 
nervous system (CNS). The amyloid cascade hypothesis postulates that it is the Aß in the SPs 
which exerts a neurotoxic effect on the different types of neurons9,13,16,27,35,44,71 and results in 
their degeneration.
A large number of neurochemical data draw attention to lesions of the cholinergic system. 
The amyloid hypothesis has also attempted to shed light on the causal relations of these 
changes. It is well documented that a correlation can be demonstrated between the increase in 
the amount of Aß and the alterations in the elements of the cholinergic system (choline 
acetyltransferase: ChAT, acetylcholinesterase: AChE, acetylcholine: ACh, the high-affinity 
choline uptake and the number of nicotinic and muscarinic ACh receptors (nAChRs and 
mAChRs). In consequence of the pathological accumulation of Aß, a cholinergic 
hypofunction will develop in the CNS. Since the cholinergic system has been proved to be 
involved in the memory function, a cholinergic hypothesis1 was formulated with respect to the 
7neuropathology of AD. The amyloid28 and the cholinergic2 hypotheses led to a need for 
further research to elucidate the role of A0 in the pathogenesis of AD.
AChE inhibitors (donepezil, rivastigmin and galanthamine) have recently been introduced 
for the treatment of AD individuals in order to increase the efficacy of the remaining ACh and 
to ameliorate the memory problems of the patients. Although there have been a large number 
of neurochemical and clinical investigations on the effects of these drugs, there is no 
morphological evidence as to how the AChE inhibitors used for the treatment of AD affect 
the various areas of the CNS and within this the different cholinergic and cholinoceptive cells. 
This thesis summarizes our efforts to shed light on the aetiology and neuropathology of this 
terrible disease.
2. REVIEW OF THE LITERATURE
2.1. Neuropathological alterations in Alzheimer’s disease
Macroscopically, the pathological hallmarks of AD, are found most frequently within the 
association regions of the cerebral cortex and within the medial temporal lobes, i.e. the hippo­
campus, amygdaloidal nuclei and parahippocampal gyri. Classically, the brains of individuals 
with AD are atrophic, with widened sulci, narrowed gyri and dilated ventricles (Fig. 1A; 
compare with Fig. IB). In microscopic investigations, two pathognomonic lesions of AD can 
be revealed. These are the SPs (Fig. ID and E) and neurofibrillary tangles (NFTs) (Fig. IF). 
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Fig. 1. Image A represents a 
control, while image B 
demonstrates an AD brain 
cross-section as seen from the 
front. In microscopic investi­
gations, no neuropathological 
alterations can be observed in 
the control cortex (C), but 
there are a large number of 
SPs (D, E) and NFTs (F) in 
the cortex of AD individuals. 
(Panels C-F taken from my 
own immunohistochemical 
preparations.) Bar = 1mm 
(C,D), 50 pm (E), 15 pm (F)
8The NFTs are composed primarily of paired helical filaments (PHFs), which may result 
from the intraneuronal accumulated neurotoxic Ap. The subunit of the PHFs is the 
microtubule-associated protein tau, which exists in the PHFs in a hyperphosphorylated, 
insoluble form. Two major types of SPs are found in the AD brain: diffuse plaques, which are 
not accompanied by abnormal neurites (Fig. 2A) and AP-containing neuritic plaques, in 
which dystrophic neurites are present (Fig. 2B,C).
Fig. 2. Image A demonstrates a diffuse SP, image B represents an neuritic SP in AD brain 
sample. (Photos taken from my preparations.) The schematic drawing (C) represents a neuritic 
SP. The dystrophic neurites (N, red) inside the SP are unusually enlarged. Other components 
of the SP are microglia (M) and astrocytes (A); the deposition of AP is shown by brownish 
lines. (This SP is a modification from R&D Systems, 2001.) Bar = 50 pm (A,B)
The SPs are extracellular lesions approximately 100 pm in size, and can be stained with 
various techniques: silver impregnation, thioflavin-S, Congo red and immunohistochemistry. 
Biochemically, the insoluble cores of the SPs have been shown to be aggregated Ap deposits, 
which consist of amyloid fibrils and are 39-43-amino acid AP peptides. The neuritic plaques 
may be more closely associated with AD since their presence correlates with regions of 
neuronal loss, and they are less frequently found in non-demented elderly patients. In addition 
to these correlative findings, the observation that microglial cells and reactive astrocytes are 
associated with virtually all neuritic plaques but with very few diffuse plaques, further 
suggests that these neuritic plaques may be critically important in the aetiology of AD.
Interestingly, neuritic and diffuse plaques may contain Api-42, Api-40, and N-terminally 
truncated AP and C-terminally truncated AP residues. Immunohistochemical studies of SPs 
with the use of antibodies specific for these Ap forms demonstrate that almost all diffuse 
plaques stain for Ap ending at residue 42 (Api-42), while far fewer contain Ap ending at
9residue 40 (AP1-40). In contrast with the diffuse plaques, the neuritic plaques often contain a 
core of both Api-40 and Api-42, with Api-42 present in the periphery of the plaque.
2.2. Relationship between the cholinergic system and Alzheimer’s disease
The idea that some of the symptoms of AD are due to a deficiency of the neurotransmitter 
ACh in the brain was first demonstrated in 1976. Later, several groups of investigators 
reported that the activities of ChAT and AChE and the level of ACh were markedly reduced 
in autopsy brain tissue from patients with end-stage AD35. Many subsequent studies have 
confirmed these findings. It has also been shown that the extent of the hypocholinergic 
activity in autopsy brain tissue correlates with the severity of the disease60 (as determined by 
the density of SPs, NFTs, or both). The cholinergic hypothesis of AD that evolved from these 
studies postulates that at least some of the cognitive decline experienced by patients with AD 
results from a deficiency of ACh, or cholinergic neurotransmission. This hypothesis has been 
the stimulus for a great deal of effort in experimental pharmacology3,17 and a large number of 
clinical trials.8,14 Loss of the neurotransmitter ACh is also thought to play an instrumental role 
in the pathogenesis of AD. The degree of cholinergic deficit is correlated with the severity of 
dementia in AD. This hypothesis has led, in turn, to promising clinical interventions (see the 
results on AChE inhibitors below). It should be emphasized, however, that ACh is not 
necessarily the only neurotransmitter involved in AD. Neurochemical research has not ruled 
out the contributions of other substances in the pathogenesis of AD.13,43
2.3. Amyloid-P neurotoxicity and Alzheimer’s disease
AD is characterized by the extracellular deposition of aggregated Ap in the brain and its 
blood vessels. Ap and its shorter fragments have been shown to be toxic to neurons in in 
vitro19 tissue cultures and to rats and aged primates in vivo.Xi AP25-35 causes morphological 
alterations in the neuronal perikarya (atrophy and degeneration) and in the axons 
(fragmentation)41, similar to those produced by the full-length Api-42. It has been suggested 
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that this 11-amino acid internal sequence of A0 is the biologically active fragment and may be 
responsible for the neurotoxic effect of A01-42.
The toxic effect of A0 has been demonstrated at micromolar concentrations in several 
tissue models.19,79 Blusztajn and Berse6 recently reported that synthetic A0 at submicromolar 
concentrations does not cause cytotoxicity, but rather reduces the expression of cholinergic 
markers in neuronal cells. The interesting question arises, therefore, of whether the neurotoxic 
effect or the reduced expression of the cholinergic marker proteins is the primary 
manifestation of the A0 effect. As mentioned earlier, AD may be characterized by a neuronal 
dysfunction in which the microtubule-associated tau-protein is abnormally 
hyperphosphorylated. If this is the case, the microtubule network is disrupted within the 
neuronal perikarya and the axonal transport may be severely affected. It may be assumed, 
therefore, that substances that are rapidly transported intraaxonally should accumulate in the 
axon after in vivo A0 treatment. We have clarified this question and demonstrated that 
proteins, including AChE, amyloid precursor protein (APP), synaptophysin (SYN) and 
vesicular acetylcholine transporter (VAChT), accumulate in damaged nerves and are good 
markers of axonal lesions present in AD. We should emphasize that there has been no 
previous report of the in vivo effects of human A01-42 on the axonal transport.
2.4. The amyloid precursor protein and presenilin in Alzheimer’s disease
2.4.1. The amyloid precursor protein
The discovery that A0 is the principal component of SPs prompted investigations into the 
origins of this peptide. Screening of cDNA libraries with oligonucleotide probes 
complementary to the A0 sequence led to the cloning of the cDNA and gene for APP. A 
number of isoforms of APP are generated by alternative splicing of a 19-exon gene, with the 
most predominant isoforms encoding for a 695-amino acid form, a 751-amino acid form and a 
770-amino acid form of APP (APP695, APP751 and APP770, respectively). Each isoform 
encodes a type-I integral membrane protein, with the A0 domain embedded in the 
transmembrane and ectodomain. APP695 is the predominant APP isoform expressed in 
neurons, whereas APP751 expression predominates elsewhere. Although the normal function 
of APP remains to be further elucidated,70 genetic studies suggest that, at least in a subset of 
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AD cases, an abnormal overproduction of Ap rather than a loss of the normal function of 
APP may be critical for the pathogenesis. These genetic studies have prompted a detailed 
investigation into the cell biology of APP processing and AP production. APP is 
cotranslationally translocated into the endoplasmic reticulum (ER) before transport through 
the secretory pathway. APP matures in the ER and the Golgi apparatus. Some of the APP is 
eventually transported to the cell surface, and reintemalized via coated pit endocytosis.45 
During the transit of APP through the ER, the Golgi, cell surface and the endosomal/lyosomal 
system, a subset of APP molecules are subject to endoproteolysis.4 Endoproteolytic cleavage 
of APP occurs at a variety of sites within the molecule (Fig. 3). The best-studied cleavage 
sites are between amino acids 16 and 17 of the AP region (a-secretase cleavage), immediately 
before Aspl of AP (p-secretase cleavage) and after amino acid 40 or 42 of the Ap domain (y- 
secretase cleavages). Cleavage of APP by P- and y-secretase releases AP, while a-secretase 
cleaves within the AP sequence and thus precludes amyloidogenesis. In a variety of non­
neuronal cell types, the principal secretory cleavage of APP occurs at the a-secretase site. 
This cleavage generates sAPP (the secreted ectodomain of APP ending at the a-secretase 
cleavage site) and C83 (the 83-amino acid COOH tail of APP). Cell surface radioiodination 
experiments have shown that the a-secretase cleavage of APP can occur at the plasma 
membrane, and the resulting APP fragment is released (or secreted) into the extracellular 
space in vivo or into the incubation medium in in vitro tissue cultures.
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Fig. 3. Schematic structure of APP and its processing by a, P and y-secretase.
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Hypotheses regarding the abundance of a 4 kD Ap species were based upon the 
demonstration that Ap is an abnormal product of APP, which is restricted to the brains of 
aged or demented humans. Several studies have recently been conducted which revealed that 
Ap might also be generated intracellularly from APP.2s A substantial increase in intracellular 
Ap suggests that Ap production from APP may be more important than previously thought in 
the pathogenesis of AD.
2.4.2. The presenilins
In 1995 a presenilin gene (presenilin-1, PS-1) was discovered, and it was demonstrated 
that missense mutations of this gene cause familial AD.72 This gene has been localized to 
chromosome 14, and presenilin-2 (PS-2) to chromosome-1. Analysis by in situ hybridization 
suggests that in the CNS, PS-1 and PS-2 mRNAs are expressed at the highest levels in 
neurons.40 PS-1 and PS-2 are integral membrane proteins that contain multiple 
transmembrane domains (Fig. 4). These proteins have a C- and an N-terminal part, to which 
specific antibodies have been developed. It is therefore possible to study in detail the neuronal 
localization and the movement of PS-1 and PS-2 within a given neuron and from this to draw
certain conclusions concerning their functions.
AB1575
Fig. 4. Schematic representation and 
topological localization of PS-1 in a 
membrane. There are eight transmembrane 
domains and C-terminal and N-terminal 
endings. AB1517 and AB3214 represent 
the antibodies specific to the C and N- 
terminals used in our
immunohistochemical and Western blot 
experiments. (Modified from R&D 
Systems, 2001.)
PS-1 and PS-2 are predominantly located within the ER and early Golgi apparatus. 
They are primarily expressed in neurons and are ubiquitously expressed within the brain. PS-1 
has been localized in the SPs and NFTs in the brain of AD individuals.7 29 In the human and 
rat CNS, PS-1 has been associated with different types of neurons and astrocytes. In the brain 
and in vitro tissue cultures, PS-1 has been found in the cell bodies and within these to be 
associated with the perinuclear envelope, the ER and the trans-Golgi network.40 PS-1 has 
been detected in the dendrites and dendritic spines, the axons and the axon terminals.7,20 In 
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developing neurons, it can be observed in the axonal growth cone. In NT2N neurons, as a 
human neuronal model system,10 and in hippocampal neuronal cultures derived from 
transgenic mice, however, PS-1 could not be found in the axons. The fragments of PS-1 have 
also been demonstrated in synaptic plasma membranes, synaptic contacts, neurite growth 
cone membranes, and clathrin-coated and small synaptic vesicles of the rat brain.5 The 
existence of PSs in the axons is debated and further evidence is needed to clarify this 
question.
We were the first to demonstrate that the PSs are not only present in the neuronal 
perikarya, but also transported in the axons. Separation of the axoplasm fractions from the 
cerebral white matter of non-demented individuals revealed the N-terminal and C-terminal 
fragments of PS-1. This finding indicated that there the intracellular trafficking of PS-1 might 
occur through the axons in the human brain. In biochemical experiments, Ray et al.66 
demonstrated that PS-1 might reach the plasma membrane, while Beher et al.5 provided 
evidence that fragments of PS-1 are present in the synaptic plasma membranes. They 
suggested that PS-1 may exit from the cell body and reach the synaptic organelles. The 
transport of PS-1 fragments in neuritic processes has also been suggested, but there was no 
direct morphological evidence for the axonal transport of PS-1.
Our studies revealed that PS-1 is present not only in the neuronal perikaryon but also in 
the axons. The presence of PS-1 in the motoric axon terminals at the neuromuscular junctions 
(NMJs) was similar to the localization of SYN, APP and VAChT.
2.5 Acetylcholinesterase inhibitors in Alzheimer’s disease
Pharmacological treatment of AD is a promising new focus for interventions. A central 
goal in AD treatment research is the identification of agents that prevent the occurrence, defer 
the onset, slow the progression, or improve the symptoms of AD.75 Progress has been made in 
this research arena, with several agents exerting beneficial effects in AD.
Recent attempts to treat AD have focused on enhancing the ACh function, using either 
cholinergic receptor agonists (e.g. nicotine) or, most commonly, AChE inhibitors (e.g. 
donepezil, rivastigmine, galanthamine and tacrine) to increase the availability of ACh in the 
synaptic cleft.78 To study the effects of drugs on the cholinergic system, it is necessary to be 
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very familial with the regional distribution of the cholinergic neurons, their axon terminals, 
and synaptic sites in non-demented and in AD individuals. The main distribution of the 
cholinergic system in the control human brain is depicted in Fig. 5.
Fig. 5. Schematic illustration of the 
cholinergic systems in the human 
brain. Note the origin of the 
cholinergic axons from the nucleus 
basalis (nb) and the medial septum 
(ms). The cholinergic axons (red 
colour) innervate the hippocampus, 
the amygdala and the various cortical 
areas. (From Perry et al., 1999.)
The first reported changes in reductions of the elements of the cholinergic system in 
autopsy samples of AD were observed in the neocortex, the hippocampus and many other 
brain regions.35 Significant deficits of ChAT and AChE activities in AD were found in the 
frontal, parietal cortical and temporal cortical regions, the hippocampus and the amygdala, the 
decrease being most severe in younger AD patients. The reductions in these enzymes and the 
number of SPs in the cortex were correlated with the loss of neurons in the nucleus basalis of 
Meynert (NBM) and the cholinergic axons in the cortex. Via histochemical demonstration of 
the AChE-positive fibres and immunohistochemical demonstration of the Aß-positive SPs 
(Fig. 6), the involvement of cholinergic neurons in AD can be well documented.
As stated above, the staining of AChE in the cortex is profoundly reduced in patients 
with AD. According to the cholinergic hypothesis of the disease, the inhibition of AChE 
activity present in the postsynaptic sites may be one of the most realistic approaches to the 
symptomatic treatment of AD.
Many neuropharmacological, pharmacokinetic and clinical studies have been 
performed on the effects of donepezil, rivastigmine and galanthamine on the cognitive 
functions.17'26
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Fig. 6. Histochemical demonstration of AChE-positive structures in the aged non-demented 
brain (A), in the affected brain (B) and in the brain of an individual with AD (C). Note the 
gradual disappearance of the cholinergic fibres and the AChE-positive cells from the various 
cortical layers. Panel B is double-stained for AChE positivity and Ap by histochemical and 
immunohistochemical means. (Photos taken from my preparations.) Bar = 150 pm
These drugs have been shown to be clinically effective and well tolerated in the 
treatment of the symptoms of mild to moderately severe AD46'21 Although the use of AChE 
inhibitors is the most highly-developed approach for the treatment of AD, there has as yet 
been no demonstration of the precise morphological sites of its action. Nor is it known how 
AChE inhibitors with known central effects influence the enzyme activities in the peripheral 
nervous system (PNS). Biochemically, donepezil has been demonstrated to inhibit AChE 
activity in the cortex, the hippocampus, the striatum and the hypothalamus of the rat brain. 
Histochemical procedures, however, have advantages over biochemical methods because they 
allow detection of the effects of AChE inhibitors at the single cell level and at a single 
synaptic site, such as the peripherally located neuromuscular junction (NMJ). During recent 
years, therefore, we have a) investigated the regional selectivity of donepezil on the AChE 
activity in the non-demented human brain; b) compared the AChE inhibitory effects of 
donepezil in the non-demented human brain with those observed in the rat brain, and c) 
investigated the AChE-inhibitory effect of donepezil at the NMJ. It was also necessary to 
establish the effects of this agent on the intensity of AChE staining in the cholinergic axons 
innervating the extra- and intracerebral blood vessels.
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3. AIMS OF THE STUDY
The present study was designed to investigate the neuropathological alterations caused by 
Api-42 in in vitro neuronal cultures and to study the effect in the CNS of donepezil applied 
for the treatment of AD.
The specific aims were:
1. To identify different transmitter-containing neurons in in vitro neuronal cultures.
2. To reveal the effects of human Ap 1 -42 on different transmitter-containing neurons in
tissue cultures (cholinoceptive, cholinergic and GABAergic).
3. To study the in vivo neurotoxic effects of human Api-42 on the axonal transport of
various proteins.
4. To demonstrate the intraaxonal transport of APP and PS-1.
5. To investigate: a) the regional selectivity of donepezil on AChE activity in the non­
demented human brain; b) the AChE-inhibitory effects of donepezil in the non-demented 
human brain in comparison with those observed in the rat brain; c) the AChE-inhibitory 
effect on the NMJ.
4. MATERIALS AND METHODS
4.1 Materials
4.1.1. Autopsy samples from human brain
We examined autopsied brains from 16 patients aged between 68 and 92 years with AD, 
and from 12 patients aged between 50 and 81 years without neurological diseases. The 
interval between death and autopsy was in all cases less than 4 h.
The human brain was sliced coronally into approximately 1 cm slabs, which were fixed 
by immersion for 24-36 h in an ice-cold 0.1 M phosphate buffer (pH 7.4) solution containing 
4% paraformaldehyde. After fixation, the samples were cryoprotected in 30% sucrose 
solution until they sank to the bottom of the container. The samples contained cortical areas, 
the hippocampal complex and the basal part of the brain. Forty-pm-thick sections were cut on 
a freezing microtome and collected in 0.9% sodium chloride buffered with 0.1 M sodium 
phosphate at pH 7.4 (PBS) containing 0.1% sodium azide.
4.1.2. Central nervous system of rat
These investigations were performed in accordance with the ethical guidelines for animal 
investigations of the Hungarian Ministry of Welfare. All experiments were carried out in 
accordance with the European Communities Council Directive (24 November 1986; 
86/609/EEC) and the Albert Szent-Gyorgyi Medical University Guidelines for Ethics in 
Animal Experiments. Every effort was made to minimize the number of animals used.
Adult Sprague-Dawley rats weighing 200-250 g were used in the experiments. The 
animals were perfused transcardially under ether anaesthesia. . Blood was first removed from 
the vascular system with PBS; the brain was then perfusion-fixed with 0.1 M phosphate 
buffer, pH 7.4, containing 4% freshly prepared formaldehyde. Thereafter, the fixative was 
removed by perfusion with 150 ml PBS. The brains were immediately removed and immersed 
overnight in a similar fixative at 4 °C. This was followed by cryoprotection for 24 h in 30% 
sucrose in 0.05 M Tris-HCl buffer, pH 7.6 (TB), at 4 °C. Frozen sections were cut coronally 
at a thickness of 30 pm and collected in PBS and processed as free-floating sections for 
histochemical staining.
4.1.3. In vitro tissue cultures from embryonic rat brain
Primary basal forebrain cultures were prepared from 16-17-day-old (El6-17) rat embryos. 
The collected tissue samples were incubated for 10 min in 0.25% trypsin (Gibco) at 37 °C. 
The tissue was mechanically dissociated by trituration with a fire-polished Pasteur pipette. 
The resulting cell suspension was centrifuged for 10 min at 1000 x g. The pellet was 
resuspended in Dulbecco's Modified Eagle Medium (DMEM) (Gibco) containing 10% fetal 
bovine serum (FBS) (Gibco), 100 U/ml penicillin and 100 pg/ml streptomycin. Cells were 
plated onto poly-l-lysine (Sigma)-coated coverslips (3.5-4xl04 cells/cm2) and were plated in a 
humidified 37 °C incubator in air containing 5% CO2.
4.1.4. Sciatic nerve of rat
Adult male Sprague-Dawley rats (4-5 months old, 400-450 g) were used in the study of 
the axonal transport of APP and PS-1. The animals were anaesthetized with a cocktail of 
ketamine (70 mg/kg) and xylazine (10 mg/kg), administered intraperitoneally. The left sciatic 
nerve of the rat was exposed and ligated distally to the obturator intemus muscle, using black 
silk thread. To visualize and quantify the anterograde and retrograde transport of PS-1 and the 
holoprotein of APP, a double-ligation procedure was applied. The right sciatic nerve was also 
exposed and a silk thread was placed loose around the nerve in the same location in the sham 
controls. The rats were allowed to recover for 6, 12 or 24 h prior to sacrifice. The ligated left 
sciatic nerve was removed; this contained a 4-mm segment above the proximal ligature, a 4- 
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mm middle segment, and a 4-mm segment below the distal ligature. Nerve segments that were 
similar in size were excised from the sham-operated animals. After different time intervals, 
the rats were anaesthetized with diethyl ether and perfused transcardially (200 ml) for 30 min 
with cold (4 °C) 4% paraformaldehyde solution, buffered with PBS. The sciatic nerves from 
the control and the ligated animals were immediately removed and immersed overnight in a 
similar fixative at 4 °C. After cryoprotection for 24 h in 30% sucrose solution, the sciatic 
nerves were cut at a thickness of 15 pm on a cryostat.
In the study of the neurotoxic effect of human Api-42 on axonal transport, adult male 
Sprague-Dawley rats (250-300 g) were used. The animals were anaesthetized and 1.0 pl of 
freshly solubilized human Api-42 (20 pM) solution was injected under the epineurium of the 
left sciatic nerve. The right sciatic nerve served as control and was injected with the A01-42 
solution vehicle. One day postinjection, the control and the Api-42-injected nerves were 
dissected out and fixed by immersion for 12 h in 4% paraformaldehyde solution. Twenty-pm- 
thick longitudinal sections were cut on a freezing microtome.
4.1.5. Spinal ganglia of rat
Adult male Sprague-Dawley rats (4-5 months old, 400-450 g) were used in the study of 
the localization of APP and PS-1. The animals were anaesthetized with diethyl ether and 
perfused transcardially (200 ml) for 30 min with cold (4 °C) 4% paraformaldehyde solution, 
buffered with PBS. The spinal ganglia (L5 and L6) were removed and immersed overnight in 
a similar fixative at 4 °C. After cryoprotection for 24 h in 30% sucrose solution, the spinal 
ganglia were cut at 24 pm on a freezing microtome and processed as free-floating sections for 
histochemical staining.
4.2. METHODS
4.2.1. AChE histochemistry
For the visualization of AChE activity, a sensitive method76 was used in a slightly 
modified form. After fixation, the tissue samples were rinsed several times in 0.1 M sodium 
maleate buffer (pH 6.0). Sections were pretreated for 20 min at 25 °C in ethopropazine 
hydrochloride (lO^M), rinsed in 0.1 M sodium maleate (pH 6.0), incubated for 80-120 min in 
a medium consisting of acetylthiocholine chloride (1.8 mM), sodium citrate (0.1 M), copper 
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sulphate (0.03 M), potassium ferricyanide (5.0 pM) and sodium maleate (0.1 M; pH 6.0), and 
rinsed in TB. Finally, the sections were placed in a solution containing 0.05% 3,3'- 
diaminobenzidine tetrahydrochloride (DAB), 0.15% nickel chloride (NiCh) and 0.03% 
hydrogen peroxide (H2O2) in TB. Sections were mounted on glass slides, dehydrated in a 
series of alcohol, cleared in xylene and coverslipped with DPX.
To determine the possible inhibitory effects of donepezil on the AChE histochemical 
staining, sections were preincubated for 20 min in PBS which contained different doses of 
donepezil (5xl0‘9, 2xl0’8, 5xl0'8, 5xl0’7 or lxl0‘6 M). Thereafter, without washing, the 
control and treated samples were placed in an incubation medium that contained the same 
dose of donepezil as was present in the preincubation solution. Control samples were 
incubated in the absence of donepezil. The muscles were incubated for 7 min, the rat brain 
tissues for 60 min, and the human brain samples for 2 h at 25 °C, with constant agitation in a 
dark box.
4.2.2. Amyloid-P peptide immunohistochemistry
For the identification of Ap the tissues were immunostained for Ap. After fixation, tissue 
samples were pretreated with concentrated formic acid, washed in PBS, soaked for 10 min in 
3% H2O2, and incubated with 2.5% Triton X-100 and then with 5% normal goat serum in 
PBS. The polyclonal antibody against the N/C-terminal of amyloid-P (1:30000) was applied 
for 24 h. This was followed by incubation with goat-anti-rabbit IgG-biotin (1:1000, Jackson 
Immunores. Lab.) for 90 min, and then with streptavidin-horseradish peroxidase (streptavidin- 
HRP) (1:1000, Jackson) for 90 min. The peroxidase reaction was developed by using DAB 
and NiCfe.
When double-stained sections were prepared, the samples were developed first in DAB 
dissolved in 0.05 M TB. The staining resulted in a brownish colour. Thereafter, the sections 
were treated for 30 min with 0.6% H2O2 to eliminate the possibly persistent activity of the 
marker enzyme. After staining for the second antibody, the peroxidase complex was 
visualized by incubating the sections in a DAB-NiCh mixture. This staining resulted in a 
bluish-black colour.
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4.2.3. Amyloid precursor protein immunohistochemistry
For the identification of APP, the tissues were immunostained for APP. After fixation, the 
sections were soaked for 10 min in 3% H2O2, and tissue samples were incubated with 2.5% 
Triton X-100, and then with 5% normal sheep serum in PBS. The monoclonal antibody 
against APP (1:2000, Boehringer) was applied for 48 h. This was followed by incubation with 
sheep-anti-mouse IgG-biotin (1:1000, Jackson Immunores. Lab.) for 90 min, and then with 
streptavidin-HRP (1:1000, Jackson) for 90 min. The peroxidase reaction was developed by 
using DAB and NiCL.
4.2.4. Presenilin-1 immunohistochemistry
For the identification of PS-1, the tissues were immunostained for PS-1. The sections 
were soaked for 10 min in 3% H2O2, washed in PBS, and treated with 0.1 M PBS containing 
0.3% Triton X-100 for 20 min, and then with 0.1 M PBS containing 5% normal rabbit serum 
for 60 min. The polyclonal antibody against PS-1 (1:45000, Chemicon) was applied for 48 h. 
This was followed by incubation with rabbit-anti-goat IgG-biotin (1:1000, Jackson 
Immunores. Lab.) for 90 min, and then with streptavidin-HRP (1:1000, Jackson) for 90 min. 
The sections were washed twice in 0.1 M PBS for 10 min between sera. When single staining 
was applied, the peroxidase complex was visualized by incubating the sections with 0.05 M 
TB containing 0.05% DAB, 0.15% NiCh and 0.005% H2O2, resulting in a bluish-black 
colour.
When double-stained sections were prepared (stained either for PS-1 and APP or for 
AChE and PS-1), the samples were developed first in DAB dissolved in TB. The staining 
resulted in a brownish colour. Thereafter, the sections were treated for 30 min with 0.6% 
H2O2 to eliminate the possibly persistent activity of the marker enzyme. In the case of PS-1, 
the second staining was for APP, while the histochemical reaction for AChE was followed by 
either PS-1 or APP immunohistochemistry. After staining for the second antibody, the 
peroxidase complex was visualized by incubating the sections in a DAB-NiCL mixture. In 
these double-stained sections, a brownish colour could be detected in some axons; in some 
others, the brownish colour was intermingled with a bluish-black colour; and in yet other 
axons, the bluish-black staining appeared as a separate entity.
4.2.5. Vesicular acetylcholine transporter immunohistochemistry
For a more exact identification of the cholinergic neurons, the tissues were 
immunostained for VAChT. After fixation, tissue samples were incubated with 2.5% Triton 
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X-100, and then with 5% normal rabbit serum in phosphate buffer. The polyclonal antibody 
against VAChT (1:32000, Chemicon) was applied for 48 h. This was followed by incubation 
with rabbit-anti-goat IgG-biotin (1:1000, Jackson Immunores. Lab.) for 90 min, and then with 
streptavidin-HRP (1:1000, Jackson) for 90 min. The peroxidase reaction was developed by 
using DAB and NiCh.
4.2.6. Synaptophysin immunohistochemistry
For the identification of neuronal synapses, the tissues were immunostained for SYN. 
After fixation, tissue samples were incubated with 2.5% Triton X-100, and then with 5% 
normal sheep serum in PBS. The polyclonal antibody against SYN (1:1000, Boehringer) was 
applied for 48 h. This was followed by incubation with sheep-anti-mouse IgG-biotin (1:1000, 
Jackson Immunores. Lab.) for 90 min, and then with streptavidin-HRP (1:1000, Jackson) for 
90 min. The peroxidase reaction was developed by using DAB and NiCh.
4.2.7. GABA immunohistochemistry
For the identification of GABAergic neurons, the tissues were immunostained for GABA. 
After fixation, tissue samples were incubated with 2.5% Triton X-100, and then with 5% 
normal bovine serum in phosphate buffer. The polyclonal antibody against GABA (1:3000, 
Immunotech) was applied overnight at 37 °C. This was followed by incubation with goat-anti- 
rabbit secondary antibody (1:30, Jackson Immunores. Lab.) for 60 min, and then with rabbit 
peroxidase-antiperoxidase complex (1:200, Nordic Immun. Lab.) for 60 min. Staining was 
revealed with a solution containing DAB, NiCh and H2O2 in TB.
4.2.8. Demonstration of amyloid-0 peptide-positive structures and acetylcholinesterase 
activity in the same tissue section
For the visualization of AChE activity, a sensitive method76 was used in a slightly 
modified form. After fixation, tissue samples were rinsed several times in 0.1 M sodium 
maleate buffer (pH 6.0). Sections were pretreated for 20 min at 25 °C in ethopropazine 
hydrochloride (10‘3 M), rinsed in 0.1 M sodium maleate (pH 6.0), incubated for 80-120 min in 
a medium consisting of acetylthiocholine chloride (1.8 mM), sodium citrate (0.1 M), copper 
sulphate (0.03 M), potassium ferricyanide (5.0 pM) and sodium maleate (0.1 M; pH 6.0), and 
rinsed in TB solution. Finally, the sections were placed in a solution containing 0.05% DAB, 
0.15% NiCh and 0.03% H2O2 in TB. Non-specific cholinesterase activity was selectively 
inhibited continuously with ethopropazine hydrochloride (lxlO-4 M) introduced directly into 
the incubation medium.
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After the demonstration of AChE-positive neurons, the tissues were immunostained for 
AP to identify the deposition sites of the peptide. After fixation, tissue samples were 
incubated with 2.5% Triton X-100, and then with 5% normal goat serum in PBS. The 
polyclonal antibody against AP (1:30000) was applied for 24 h. This was followed by 
incubation with goat-anti-rabbit IgG-biotin (1:1000, Jackson Immunores. Lab.) for 90 min, 
and then with streptavidin-HRP (1:1000, Jackson) for 90 min. The peroxidase reaction was 
developed by using DAB.
4.2.9. Western immunoblotting 
Preparation of the sciatic nerve for SDS-PAGE
The control and ligated sciatic nerves were removed after ligation for 6, 12 or 24 h. 
Segments 4 mm in length of the sciatic nerves of the sham-operated control animals, and 4­
mm segments from above the proximal ligature, from between the two ligatures, and from 
below the distal ligature of the sciatic nerve were excised on ice and immediately placed into 
a buffer solution which contained TB at pH 7.5, 150 mM NaCl, 2 mM
ethylenediaminetetraacetic acid (EDTA), 2 mM phenylmethylsulfonyl fluoride (PMSF), 2 
pg/ml leupeptin, 1 pg/ml pepstatin and detergents (1% Nonidet-P-40 and 0.1% sodium 
deoxycholate). Thereafter, the samples were homogenized. As the amount of PS-1 in the 
sciatic nerve was expected to be low, samples from two animals were pooled for PS-1 
isolation. After centrifugation (10000 x g for 1 h at 4 °C), the proteins in the supernatant 
solutions were measured by the method of Hess. For analysis, 40 pg of protein was 
supplemented with Laemmli sample buffer and, after boiling for 5 min, loaded on 9.0% 
polyacrylamide gel for electrophoresis.
Western blot analysis
To ascertain whether only the C-terminal and N-terminal fragments, or the holoprotein of 
PS-1, or all of these, are transported in the sciatic nerve of rat, we used various polyclonal 
antibodies: AB5308 for the detection of the intact 45 kDa holoprotein and the C-terminal 
fragment [amino acids 275-367] and AB 1575 to recognize the full-length and the N-terminal 
fragment [amino acids 14-33] of PS-1.
The separated proteins were transferred to nitrocellulose membranes by using the BioRad 
Mini-Protean II system. Membranes were blocked in 5% non-fat dry milk with 0.2% Tween- 
20 in 50 mM TBS for 1 h at room temperature. For the labelling of the fragments and the 
23
holoprotein of PS-1, the antibodies were used in a dilution of 1:1000 in TBS containing 1% 
non-fat dry milk. The nitrocellulose membranes were incubated with the different primary 
antibodies overnight at room temperature. After the membranes had been washed five times 
in TBS, the filters were incubated with horseradish peroxidase-conjugated goat anti-rabbit 
IgG (1:5000) or horseradish peroxidase-conjugated rabbit anti-goat IgG (1:5000) as secondary 
antibody for 1 h at room temperature, followed by washing as described above. Bound 
antibodies were detected with the Supersignal Western blot chemiluminescence reagent, and 
this was followed by exposure to an autoradiography film.
Quantitation of blots
Optical densities (ODs) of immunoreactive bands were quantified by means of the NIH- 
Image program (NIH, USA). The intensity of the control band was taken as 100%, and 
changes were calculated with respect to this value. The reported data are the overall results of 
three different experiments. The error bar denotes the S.E. A probability level P<0.05 was 
taken to be statistically significant. Statistical evaluations were performed with Student’s t- 
test.
4.2.10. Image analysis
In some of our experiments, image analysis was used. The OD in areas comprising the 
stained perikarya, dendrites and axons and the number of immunoreactive axonal varicosities 
was determined with a Quantimet 500MC Image Analysis System (Leica Cambridge) linked 
to a JVC-Color camera mounted on a Leica Laborlux “S” Leitz microscope.
The histochemical reactions were visualized and the digitized image (256 grey levels) 
was displayed on a colour monitor with 1024x768 pixel resolution. Five fields of each site 
were chosen at random. The fields of interest were measured and the OD measurements were 
averaged. All measurements were made under the same optical and light conditions.
5. RESULTS
5.1. In vitro experiments
5.1.1. Identification of cholinergic neurons and their axons in in vitro cell cultures (VI)
In the control tissue cultures (DIV7 to 17), the various types of cholinergic neurons 
(bipolar and multipolar) and the VAChT-immunoreactive axons, their varicosities and axon 
terminals could be revealed among many non-cholinergic cells. The VAChT 
immunoreactivity was observed mainly as puncta, and to a lesser extent as diffuse staining in 
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neurons of different sizes. The VAChT-immunoreactive axon terminals were present on the 
soma and dendrites of cholinoceptive and cholinergic cells (Fig. 7B-E).
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Fig. 7. Identification of cholinergic cells in in vitro tissue cultures with VAChT 
immunohistochemistry. Note the absence of immunostaining in a non-cholinergic multipolar 
cell (A), and the presence of VAChT-positive axon terminals on a cholinoceptive cell (B, 
arrow) and on a cholinergic neurons (C, arrow). In panel D, a VAChT-positive axon terminal 
innervates (yellow arrow) a dendrite of a non-cholinergic cell (black arrow). The distribution 
of VAChT-positive axon varicosities is presented in panel E. The SYN-positive axon 
terminals are present in a similar localization on the perikarya of a multipolar cell (F, arrow). 
Bar = 20 pm (A-D,F) or 10 pm (E) (Photos taken from my preparations.)
5.1.2. Neurotoxic effect of amyloid-pi-42 on cholinergic nerve cells in in vitro tissue 
cultures (VI)
After identification of the cholinergic neurons and their axon varicosities, we set out to 
study whether Api-42 affects these neurons and their axon terminals. Using VAChT 
immunohistochemistry in control neuronal cultures derived from the basal forebrain on El8 
and cultured for various time intervals (E18DIV7, E18DIV14 and E18DIV17), the density of 
the immunoreactive axons gradually increased (Fig. 8A-C). When similar neuronal cultures 
were treated for 2 days on days 5, 12 and 15 with 20 pM Api-42, all the VAChT 
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immunoreactivity disappeared from the axon terminals (Fig. 8. D-F). This result suggests that
Ap in in vitro tissue cultures is very harmful to cholinergic neurons and their processes.
Fig. 8. Light microscopic 
localization of VAChT 
immunoreactivity in the 
cholinergic axon varicosities 
and in the axon terminals. 
Note that the numbers of 
small and large labelled 
puncta increase during the in 
vitro development of 
cholinergic neurons (A: 
DIV7; B: DIV14; and C: 
DIV 17). After treatment with 
20 pM Api-42 for 2 days, 
the VAChT immuno­
reactivity disappears in the 
basal forebrain tissue culture 
(D: DIV7; E: DIV14; and F: 
DIV 17). Bar = 20 pm. (Papp 
et al., 2001, in press)
Using image analysis, we next determined the number of VAChT axon varicosities of the 
cholinergic neurons during development in in vitro tissue cultures. Evaluation of the VAChT-
positive axon varicosities and axon terminals in the control and Api-42-treated samples is
illustrated in Fig. 9.
Fig. 9. Evaluation of VAChT- 
positive axon varicosities and/or 
axon terminals by image analysis 
in control and Ap 1 -42-treated 
basal forebrain tissue cultures. 
The control samples were treated 
with the vehicle, and the other in 
vitro cultures with 20 pM Api-42 
for 2 days on days 5, 12 or 15. 
(Papp et al., 2001, in press)
5.1.3. Neurotoxic effect of amyloid-pi-42 on synaptophysin-immunopositive axon 
terminals in in vitro tissue cultures. A comparative investigation with that of vesicular 
acetylcholine transporter immunostaining (VI)
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In this comparative investigation, we were interested in whether Api-42 acts only on the 
cholinergic neurons, or whether it exerts a more general effect and degenerates non- 
cholinergic nerve cells as well. If this is the case, we could demonstrate that the number of 
SYN-positive axon varicosities is reduced better than that of the VAChT-positive axon 
varicosities. In control tissue cultures, the SYN-positive immunoreactive axon varicosities 
and the axon terminals could be revealed diffusely distributed among neurons of various 
sizes. They were present on the soma of the neurons and closely related to some dendrites. 
The SYN-immunopositive structures differed considerably in size. The number of axonal 
varicosities increased as the duration of cultivation progressed (Fig. 10. A-C) After 20 pM 
Api-42 treatment of the basal forebrain tissue cultures for 2 days, the numbers of SYN- 
positive structures were diminished on DIV7, DIV14 and DIV17 (Fig. 10. D-F).
Fig. 10. Light microscopic localization of 
SYN immunoreactivity in the axon 
varicosities and in the axon terminals 
during development in the control basal 
forebrain neuronal cultures. Note the 
increased density of staining after the 
various time intervals. A: DIV7; B: 
DIV14; and C: DIV17. The SYN- 
immunore-active axon varicosities are 
reduced in the cultures after treatment with 
20 pM Apl-42 for 2 days (D: DIV7; E: 
DIV 14; and F: DIV 17). Bar = 20 urn. 
(Papp et al., 2001, in press)
For quantitative determination, the numbers of SYN-positive axon varicosities in the 
control and the Ap-treated samples of the cultures were investigated by means of image 
analysis at various times (DIV7, DIV 14 and DIV 17). The results of the analyses of the control 
and Ap-treated samples are summarized in Fig. 11.
Fig. 11. Evaluation of SYN-positive axon 
varicosities and/or axon terminals by image 
analysis in control and Ap 1-42-treated basal 
forebrain tissue cultures. The control samples were 
treated with the vehicle, and the other in vitro 
cultures with 20 pM Api-42 for 2 days on days 5, 
12 or 15. (Papp et al., 2001, in press)
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5.1.4. Neurotoxic effect of amyloid-pi-42 on acetylcholinesterase-positive nerve cells in 
in vitro tissue cultures (V)
In earlier experiments, we demonstrated the neurotoxic effect of Apl-42 on the 
VAChT-positive cholinergic nerve cells (Section 5.1.2.) and on the SYN-positive axon 
varicosities (Section 5.1.3). These results suggested that Api-42 acts not only on the 
cholinergic neurons, but also on other non-cholinergic and AChE-positive cells as well. 
Histochemical evidence in support of this suggestion is presented below.
In the control basal forebrain cultures (E16DIV4), the specific staining for AChE was 
evenly distributed in the perikarya and processes of the neurons (Fig. 12. A). After treatment 
with 20 pM Api-42 for 24 h (E16DIV4+1), the localization of the staining pattern was 
changed. The ACh-positive reaction sites appeared to be present either dislocated to one area 
of the cell body (Fig. 12. B) or in one segment of the dendrite only (Fig. 12. C). After 3 days 
of in vitro treatment (E16DIV4+3), the AChE reaction end-product could be detected only in
the degenerated dendrites (Fig. 12. D).
Fig. 12. AChE histo­
chemistry in in vitro 
neuronal cultures. Note 
the pattern of enzyme 
staining in the control 
sample (A) and after 
Apl-42 treatment (B-D). 
Bar = 25 pm (Pakaski, 
Papp et al., 1999.)
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5.1.5. Neurotoxic effect of amyloid-pi-42 on GABAergic nerve cells in in vitro tissue 
cultures (IV)
In these experiments, we examined whether Api-42 has a neurodegenerative effect on 
GABAergic nerve cells.
The staining pattern of the control cultures demonstrated a diffuse intracellular 
distribution of GABA in the perikarya and long processes of the neurons (Fig. 13. A-C). The 
neurons in the culture exposed to 20 pM Api-42 revealed characteristic morphological 
changes: 1 day after Apl-42 treatment (DIV4+1), varicosities could be detected on the axons 
and terminal arborization of a large number of neurons (Fig. 13. D). By day 3 after Api-42 
incubation (DIV4+3), not only were varicosities visible on all the processes of the neurons 
(Fig. 13. E), but the number of GABA-immunoreactive neurons was also decreased. Five 
days after ApPl-42 exposure (DIV4+5), the GABA immunoreactivity was restricted to the 
perikarya in most of the positively stained neurons (Fig. 13. F), and the number of 
GABAergic cells was further decreased. The GABA-positive cells exhibited morphological 
indications of process degeneration.
Fig. 13. Immuno­
histochemical stain­
ing of GABAergic 
neurons. Note the 
intactness of the 
neuronal perikarya 
(arrows in B and C) 
and axons of the 
GABA-positive cells 
(A-C and caged area 
in C). After 20 pM 
Api-42 treatment, 
the neuronal peri­
karya are rounded 
(arrows in E and F) 
and the axons and 
axon terminals are 
fragmented (caged 
area in D). Bar = 25 
pm (A) or 10 pm (C­
F). (Pakaski, Papp et 
al., 2000)
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5.2. In vivo experiments
5.2.1. Axonal transport of presenilin-1 (III)
APP and PS-1 are not only of importance for the normal functioning of the various 
neurons, but also play central roles in the pathogenesis of AD.4,12 First, we studied the 
axonal transport of PS-1 in a spinal cord-sciatic nerve-NMJ model system in rat.
PS-1 immunoreactivity was revealed in a discontinuous manner in a number of axons in 
the control sciatic nerve (Fig. 14. A). Similar axonal staining was seen in the sensory axons 
leaving the L5 and L6 dorsal root ganglia and in a number of Schwann cells around the 
myelinated axons. In the double-ligated samples, PS-1 was accumulated above the upper 
ligature (Fig. 14. D) and below the lower ligature (Fig. 14. E) after 6, 12 and 24 h. Between 6 
and 24 h, however, the PS-1 staining gradually increased only on the proximal side. The 
staining was always more intensive in the segment proximal to the ligatures than below the 
lower ligature. Between the two ligatures, PS-1 staining was observed only in the cytoplasm 
of the Schwann cells (not demonstrated) after 24 h. The results of immunohistochemistry as 
concerns the anterograde and retrograde transport of PS-1 were verified by semiquantitative 
Western blot studies.
Fig. 14. Immunohistochemical 
demonstration of PS-1 in the various 
tissues. PS-1 staining appears in a 
discontinuous manner (arrows) in the 
axons of the control sciatic nerve 
bundle (A). No immunoreactivity was 
detected in the sciatic nerve samples 
without primary antibody (B). The 
arrangement of the double ligation on 
the sciatic nerve is demonstrated in C, 
where U indicates the segment above 
the proximal ligature (arrow), M the 
segment between the ligatures, and L 
the segment below the lower ligature 
(arrowhead). After 24 h of double 
ligation, a pronounced accumulation 
of PS-1 occurred above the proximal 
ligature (D, arrows). In the segment 
below the lower ligature, the staining for PS-1 was less expressed (E, arrows). PS-1 
immunoreactivity occurred in the perikarya of the motoneurons (F) and the sensory nerve cell 
bodies of various sizes of the dorsal root ganglia (G). Scale bar = 50 pm (A, B, F, G), 1.0 mm 
(C) or 25 pm (D, E). (Kasa, Papp and Pakaski, 2001)
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Western blotting confirmed the accumulation of the ~20-kDa C-terminal and ~25-kDa N- 
terminal fragments and the full-length 45-kDa holoprotein of PS-1 both above and below the 
ligature (Fig. 15).33
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Fig. 15. Western blot of protein extracts from control samples (a) and from samples double­
ligated for 6 h (b), 12 h (c) or 24 h (d) above the proximal ligature, or for 6 h (e), 12 h (f) or 
24 h (g) below the distal ligature of the sciatic nerve. The polyclonal antibody AB5308 
detected ~20-kDa protein (A) corresponding to the C-terminal PS-1 and intact ~45-kDa 
protein (E), while antibody AB 1575 detected ~25-kDa protein (C) corresponding to the N- 
terminal PS-1. The immunoblot results in A, C and E were quantified and are demonstrated in 
histograms B, D and F, respectively. The OD is expressed as a percentage of that for the 
control sample (100%). The reported data are the overall results of three different 
experiments. The error bar denotes the S.E. Statistical evaluations were performed with 
Student’s /-test. Significant difference from the control sample: * P<0.05, ** P < 0.001. 
(Kasa, Papp and Pakaski, 2001)
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5.2.2. Axonal transport of amyloid precursor protein
Although the anterograde transport of APP in the sensory axons of the sciatic nerve has 
already been described38, we re-examined the question of whether APP is transported only in 
an anterograde direction or similarly to that of PS-1. In the control nerve, the APP staining 
appeared in a similar localization and axonal distribution as for PS-1 (Fig. 16. A). When the 
nerves were removed after 6, 12 or 24 h, the accumulation of APP in the axons, similarly to 
that of PS-1, was revealed both proximally (Fig. 16. B) and distally (Fig. 16. C) to the 
ligatures. In a number of axons, the staining in the axoplasm was particularly intense on the 
proximal side, relative to the distal side.
Fig. 16. Immunohistochemical demonstration of APP in the control (A, arrows) and double­
ligated (B,C) sciatic nerve of rat. After 24 h of double ligation, a pronounced accumulation of 
APP occurred above (B, arrows) and below (C, arrowheads) the ligature.
Scale bar = 25 pm.
To quantify the immunohistochemical results, Western blot experiments were carried out 
in the control and the double-ligated sciatic nerve (Fig. 17, panel A). Both 94-kDa and 116- 
kDa APP were present in the control sample (a) and the amounts of these forms accumulated 
above the proximal ligature up to 6 h (b), 12 h (c) and 24 h (d). After accumulation for 6 h (e), 
the amounts below the lower ligature decreased (f, g). The Western blot results were 
quantified and are demonstrated in histograms (panels B-D). The amounts of 94-kDa plus 
116-kDa APP are depicted in panel B. The difference in the accumulation of 94-kDa and 116- 
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kDa APP is represented in panels C and D, respectively. These results59 clearly demonstrate 
that APP is transported in both the anterograde and the retrograde direction in the sciatic 
nerve of rat.
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Fig. 17. The APP Western blot results 
on the ligated sciatic nerve (A). The OD 
in panels B-D is expressed as a 
percentage of that for the control sample 
(100%). Data are given as means ±
S.E.M. Statistical evaluations were 
performed with Student’s /-test. * sig­
nifies p < 0.01. Number of determin­
ations = 3.
5.2.3. Transport of amyloid precursor protein and presenilin-1 in the motoric axons of 
the sciatic nerve of rat
The next question was to ascertain whether APP and PS-1 are transported in the motoric 
nerves or the sensory nerves or both. For this, double staining of the sciatic nerve for AChE 
and PS-1 or for AChE and APP was carried out in the sciatic nerve of rat (Fig. 18). The 
results33 demonstrated overlapping immunoreactivity of APP and AChE and of AChE and 
PS-1 in the motoric axons, suggesting that both proteins reach the axon terminals and, after 
functioning there, return with information to the cell body.
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Fig. 18. Double-stained samples for 
AChE and PS-1 (A-C), for AChE and 
APP (D,E) and for PS-1 and APP 
(G). In the sciatic nerve double­
ligated for 24 h and double-stained 
first for AChE (brown, arrowhead) 
and thereafter for PS-1 (bluish-black, 
arrow), the two types of staining 
appeared either in distinct regions 
within the same axon (A), or in 
different axons (B), or in the same 
areas of the fibres (C) above the 
proximal ligature. In C, the PS-1 
immunoreactivity is present in dot­
like structures (arrow) in the region 
where the AChE (arrowhead) is 
present. In samples first stained for 
AChE (D, arrowheads) and thereafter 
for APP, either the two reaction end-products appeared in the same some axon (E, arrowhead 
plus arrow), or the AChE positivity (arrowheads) and the APP immunoreactivity (arrows) 
were present in separate fibres (E). The immunoreactivity for PS-1 (F, arrows), PS-1 and APP 
(G, arrows) could be revealed above the ligature in the same areas of the same axon in the 
sciatic nerve double-ligated for 24 h. In the muscle samples, the APP (H) and PS-1 (I) 
immunoreactivity appears as discrete dots (arrowheads). In double-stained muscle samples, 
the postsynaptic sites were delineated by the AChE histochemical reaction (J, K, brown), 
while the PS-1 immunoreactivity appeared in the motoric axon (J, arrow) and in the 
presynaptic axon terminals (J, K, arrowheads) at the NMJ. (Kasa, Papp and Pakaski, 2001) 
Bar = 25 pm (A-G), 10 pm (H-K).
5.2.4. In vivo neurotoxic effect of human amyloid-pl-42 on axonal transport (II)
The neurotoxic effect of Api-42 in the pathogenesis of AD is important. Here, we 
provide experimental evidence that such an effect in vivo may be due to the inhibition of 
axonal transport in the neurons.
Our results demonstrated that exogenously applied human Api-42 could disturb the 
axonal transport of AChE, APP, VAChT and SYN in the sciatic nerve of rat (Fig. 19; a 
detailed description of the results can be found in paper II). The accumulation of 
immunoreactivity was restricted to the area where Api-42 was present.
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Fig. 19. Ap staining could not be 
detected in the control nerve 
trunk of rat (A). After the 
application of human Api-42, 
however, dark staining could be 
observed at the injection site 
among the myelinated axons (B) 
and at the node of Ranvier (C, 
D). In the control sciatic nerve, 
AChE staining was demon­
strated in the cholinergic axons, 
as described earlier. In the nerve 
trunk treated with Api-42 for 24 
h, a considerable accumulation 
of AChE occurred at the injected 
site (F, G). In the control sciatic 
nerve, no immunohistochemical 
staining of APP, VAChT and 
SYN could be observed. 24 h 
after the injection of Apl-42, the 
APP (H), VAChT (I) and SYN 
(J) reactions were present in the 
axonal swellings, indicating 
local axonal injuries. (Kasa, 
Papp et al., 2000)
5.3. Effects of acetylcholinesterase inhibitors
5.3.1. Effects of acetylcholinesterase inhibitors in autopsy human brain samples (I)
Although the use of AChE inhibitors is the most highly developed approach for the 
treatment of AD, the precise morphological sites of their action have as yet not been 
demonstrated. Nor is it known how AChE inhibitors with known central effects influence the 
enzyme activities in the PNS. This part of this thesis relates to the effect of donepezil on the 
AChE activity in human autopsy brain samples. Donepezil is used for the treatment of 
patients with AD. (A detailed description of the results obtained on donepezil can be found in 
paper I.)
The AChE-positive structures in the different areas of the human brain proved to be 
sensitive to donepezil in a dose-dependent manner. The most important finding in this
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experiment was that donepezil inhibited the AChE activity in the postsynaptic cholinoceptive 
neurons more effectively than that in the presynaptic cholinergic axons. Donepezil (2x10‘8 M) 
inhibited most of the AChE-positive neurons and reduced some of the axonal staining in the
temporal cortex (Fig. 20).
Fig. 20. Photographs showing the 
differences in AChE activity between the 
control (A) and the donepezil-treated (B) 
human temporal cortex. Note the presence 
of intensely-stained pyramidal cells 
(arrows) and the AChE-positive nerve fibres 
in the control sample (A), and the 
disappearance of AChE activity from most 
of the neuronal perikarya (arrows) in the 
AChE-positive nerve fibres in the control 
sample (A), and the disappearance of AChE
activity from most of the neuronal perikarya (arrows) in the 2x10‘8 M donepezil-treated 
sample (B). A stained neuron can rarely be observed in the donepezil-treated sample, though 
some AChE positivity is still present in many cholinergic nerve fibres (arrowheads) (B). Scale 
bar = 50 pm. (Kasa, Papp et al., 2000)
For quantitative analysis of the inhibitory effect of donepezil, we measured the changes in 
AChE histochemical staining in the AD brain. The results revealed a dose-dependent 
inhibitory effect of donepezil in the various areas of the cortex, the hippocampus, the caudate- 
putamen and the NBM of the human brain (Fig. 21).
EFFECTS OF DIFFERENT DOSES OF DONEPEZIL
Fig. 21 Changes in OD in the 
AChE histochemical staining in the 
various areas of the human brain 
after treatment with different doses 
of donepezil. The OD of the AChE 
histochemical reaction in the 
control sample is taken as 100%. 
Five fields of each area of interest 
were measured (n = 5) and the OD 
results were averaged. Symbols are 
as follows: putamen ( • ), NBM 
( ▲ ), hippocampus CAI ( ■ ), 
hippocampus CA3 and CA2 ( ▼ ), 
hippocampus CA4 ( □ ), temporal 
cortex ( ♦ ), entorhinal cortex 
( V) and insular cortex ( O ). 
(Kasa, Papp et al., 2000)
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5.3.2. Effects of acetylcholinesterase inhibitors in rat brain (I)
Similarly as in the human brain (see above), various concentrations of donepezil (5x1 O'9 
M, 2xl0’8 M, 5xl0'8 M, 5xl0‘7 M and lxlO'6 M) dose-dependently inhibited the AChE 
staining in the various areas of the rat brain. The detailed results of these experiments can be 
found in paper I. For quantitative analysis of the inhibitory effect of donepezil, we measured 
the changes in the OD of AChE histochemical staining. The results revealed a dose-dependent 
inhibitory effect of donepezil in the various areas of the cortex, the hippocampus, the caudate- 
putamen and the NBM. The quantitative OD results relating to the inhibitory effects of 
donepezil on the AChE histochemical staining in the rat brain are presented in Fig. 22.
EFFECTS OF DIFFERENT DOSES OF DONEPEZI Fig. 22. Changes in OD in the AChE histochemical 
staining in the various areas of the rat brain after 
treatment with different doses of donepezil. The OD 
of the AChE histochemical reaction in the control 
sample is taken as 100%. Five fields of each area of 
interest were measured (n = 5) and the OD results 
were averaged. Symbols are as follows: caudate 
putamen ( • ), NBM ( ▲ ), hippocampus CAI ( ■), 
hippocampus CA3 and CA2 ( ▼ ), hippocampus 
CA4 ( □ ), fronto-parietal cortex ( O ) and primary 
olfactory cortex ( A ). (Kasa, Papp et al., 2000)
During the treatment of human patients with donepezil, the fasciculation of different 
muscles can occur. Among others, we studied the inhibitory effect of donepezil on AChE 
activity at the NMJ. The results showed that donepezil has not only an AChE-inhibitory effect 
in the various areas and in the various neuronal structures in the CNS, but also an undesired
effect at the NMJ (Fig. 22). Fig. 23. Photographs showing the AChE 
activity of the NMJ in the diaphragm of a 
control rat (A). Heavy AChE reaction end­
product is present in the control sample (A). 
The application of 2x10’8 M donepezil 
reduced the enzyme staining slightly (B), 
whereas 5x1 O’7 M donepezil did so strongly 
(C) in the motor end-plate. Scale bar = 50 
pm. (Kasa, Papp et al., 2000)
These histochemical results provide the first morphological evidence that, under in vitro 
circumstances, donepezil is not a general AChE inhibitor in the CNS, but rather selectively 
affects the different brain areas and, within these, the cholinergic and cholinoceptive 
structures.
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6. DISCUSSION
6.1. Toxicity of amyloid-pi-42 in in vitro cell cultures
To explain the massive neuronal loss in the brain of AD patients, several models have 
been proposed, Ap being implicated as the principal culprit.30,41 Indeed, according to the 
amyloid cascade hypothesis™ Ap may play key roles in the AD pathology, although the 
mechanism by which it becomes involved in the neurodegeneration is still unclear. In this 
context, it is worthwhile to mention that Ap is not a pathological product, but a physiological 
product found in the culture-conditioned medium or cerebrospinal fluid. This suggests that, 
besides its well-known pathological function, Ap has a physiological function too.
The earlier neurochemical and neuropathological data emphasized the relatively selective 
vulnerability of the cholinergic system to Ap, which led to the cholinergic hypothesis? 
However, data accumulated which indicated that, besides the cholinergic neurons1,16, other 
transmitter-containing neurons undergo degeneration in AD.9,27,43,77
The establishment of in vitro systems that can recapitulate some aspects of the 
pathogenesis of AD is of utmost importance for an advancement of our understanding of the 
disease mechanism. Although the neurotoxicity of Ap has been observed in various cell 
cultures,19,79 no in vitro or in vivo data were earlier available relating to comparisons of the 
vulnerability of cholinergic, cholinoceptive and GABAergic neurons to AP toxicity. Our 
study for the first time identified the cholinergic neurons in in vitro tissue cultures53,54 and 
revealed that Api-42 and its fragments (AP31-35 and AP34-39) are toxic not only to 
cholinergic neurons, but also to cholinoceptive and GABAergic neurons in basal forebrain 
cultures.51,52,55'58 The toxic effect predominated mainly on small, bipolar neurons, while the 
large multipolar neurons displayed more resistance to Ap. Our results are in contradiction 
with the data of Pike and Cotman,62 who found that GABAergic neurons are resistant to Ap 
treatment. We hypothesize that the apparent controversy may arise from differences in the 
solvent and in the concentrations of the peptides applied in the different experiments. Another 
difference lies in the age and origin of the cultures used by our group and by Pike and 
Cotman. It is unclear how AP may have a toxic effect on the various types of neuronal 
cultures. It has been suggested that it is not the soluble form,47 but rather the aggregated form 
of Ap which is toxic in in vitro tissue cultures. However, it seems unlikely that aggregated AP 
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peptide may interact with specific binding sites of the neuronal perikarya and axonal 
membrane. A more plausible explanation would be direct surface interactions between A0 
and the lipid bilayer present in the membranes. In support of this suggestion, A£ was also 
found to be toxic when it was applied as a fresh solution. The concentration of the peptide 
applied in in vitro tissue cultures is important. It has been found that a low concentration 
(below 1 pM) may have a trophic effect, while at high concentrations (above 10 pM) it has a 
neurotoxic effect.80 In our experiments, 20 pM AP was found to be neurotoxic to cholinergic, 
cholinoceptive and GABAergic neurons. Our in vitro tissue culture data are therefore in close 
relationship with data found on AD patients: besides the cholinergic neurons, other 
neurotransmitter systems may be involved in the aetiopathology of the disease.27,77
6.2. In vivo effect of amyloid-pi-42 on axonal transport
The typical neuropathological features of AD include the cerebral deposition of A01-42 in the 
SPs and the degeneration of cholinergic nerve cells.35 The disease is characterized by a 
neuronal dysfunction in which the microtubule-associated tau-protein is abnormally 
hyperphosphorylated, which in turn may cause a disruption of the microtubule network and 
affect the axonal transport. If this suggestion is correct, it may be assumed that substances that 
are rapidly transported axonally should accumulate in the axon after AP treatment. It was 
earlier demonstrated that proteins, including AChE,69 APP,38,61,73 SYN and VAChT,42 
accumulate in a nerve trunk when it is damaged by mechanical lesions. There had been no 
previous report of the in vivo effects of human Api-42 on the axonal transport of these 
proteins. We therefore used membrane-bound proteins to demonstrate the neurotoxic effects 
of Api-42 on axonal transport. A new experimental set-up was introduced to study the 
possible in vivo effect of Ap on the axonal transport of various enzymes and axonal proteins. 
It was found that under in vivo circumstances Ap very effectively inhibited the transport of 
different proteins.32
The mechanism whereby AP can block the fast axonal transport of AChE, APP, VAChT 
and SYN is not clear at present. Several hypotheses have been put forward to explain the 
neurotoxic effect of Ap.19 It has been amply demonstrated that the aggregated and soluble 
forms of the peptide are very harmful to neurons and endothelial cells both in vitro36,31'52 and 
in vzvo.18,24 Extracellularly applied AP was internalized selectively by hippocampal CAI 
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neurons and caused the accumulation of amyloidogenic carboxy terminal fragments of APP. 
In our experiments, the immunohistochemical localization of the injected peptide suggested 
that it could be internalized into the axoplasm at the nodes of Ranvier. If this is the case, A0 
may inhibit the transport inside the axon by affecting dynein, the dynactin complex and the 
kinesin system, known to be responsible for the fast axonal transport. When Ap is applied 
exogenously, the accumulation of APP is regulated by tau-protein kinase I/glycogen synthase 
kinase-3p, resulting in an impairment of axonal transport and in the cytoplasmic accumulation 
of APP. The results of this study support the suggestion that AD may be initiated by a failure 
in axonal transport, which is followed by neuronal degeneration.
6.3. Effect of donepezil on acetylcholinesterase activity in central and peripheral nervous 
tissues
In biochemical experiments, donepezil has been shown to inhibit AChE activity in the 
human brain and in human erythrocytes. Neurochemical studies have demonstrated that 
presynaptic cholinergic markers such as ChAT, the ACh level and the high-affinity choline 
uptake are significantly reduced in the cortex, the hippocampus and the NBM in AD.35 Since 
the neocortex and the hippocampal formation are known to be major sites of the 
neuropathologic changes in AD, inhibition of the residual AChE activity in these areas might 
well be beneficial in alleviating the cholinergic hypofunction in AD. Indeed, in clinical 
applications, donepezil is used for the treatment of memory loss and the behavioural 
deterioration associated with the ACh deficit in AD.3,14
Biochemical experiments have demonstrated that AChE and its different molecular forms 
(soluble and membrane-bound) are reduced in the brain in AD64,65 and anomalous AChE 
activity appears in the SPs and cerebrospinal fluid. This histochemical study revealed the 
noteworthy finding that the AChE activity present in the postsynaptic cholinoceptive cortical 
pyramidal cell body is more sensitive than the presynaptic cholinergic axons to donepezil. (It 
is interesting to note that the cholinergic neurons present in the NBM, which receives 
cholinergic innervations and may therefore be regarded as cholinoceptive, are not as sensitive 
to donepezil as the purely cholinoceptive pyramidal cells within the cortical layers.31) Our 
results therefore provide the first morphological evidence of a difference in the effects of 
donepezil on the presynaptic cholinergic and postsynaptic cholinoceptive sites in the human 
brain. Similarly to our results, in biochemical experiments where donepezil was added to 
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soluble and crude mitochondrial fractions obtained from non-demented or AD brain, the 
AChE activity was inhibited in the soluble and the particulate fractions at a low concentration 
of the inhibitor. Donepezil inhibits the postsynaptic AChE activity better than the presynaptic 
AChE activity, which is quite remarkable. By slowing down the hydrolysis of ACh at the 
synaptic sites, donepezil will enhance the effect of the residual cholinergic presynaptic 
elements in AD. These results are similar to those observed for heptyl-physostigmine.
In biochemical experiments, donepezil has been shown to inhibit the AChE activity in the 
brain, the cortex and the hippocampus of rat. It elevates the extracellular levels of 
catecholamines and ACh in the cerebral cortex and the hippocampus. In vitro experiments49 
revealed that the IC50 of donepezil on the AChE activity present in the homogenate of the rat 
brain cortex is around 10'8 M, which is somewhat less than suggested by our OD experiments. 
The differences can be explained, however, in terms of the methods used in the various 
studies. In in vivo animal studies, donepezil has been demonstrated to improve the working 
memory.22
The in vivo inhibitory effect of donepezil on AChE activity has also been investigated in 
the frontal cortex, the hippocampus, the striatum and the hypothalamus of rat. Biochemical 
studies suggested that the different doses of donepezil inhibited the AChE activity in the 
frontal cortex more markedly than that in the striatum. Our histochemical results clearly 
demonstrated that the different neuronal elements (cell bodies and axonal processes) in the 
various brain regions are affected differently, and even within the same region, such as the 
cortex, the hippocampus, the NBM and the striatum. This therefore provides firm 
morphological evidence that the cholinoceptive pyramidal neuronal perikarya are more 
sensitive than the cholinergic presynaptic axons in the cortex and the hippocampus of rat to a 
given concentration of donepezil. On the other hand, the neuronal cell bodies in the NBM, 
from where the cholinergic axons emanate to various areas of the cortex, are moderately 
resistant to donepezil inhibition. We found that the most resistant AChE-positive neuronal 
perikarya are located in the putamen, the NBM, the diagonal band of Broca and some cells in 
the hypothalamus. As an alternative interpretation, higher concentrations of donepezil are 
needed to inhibit AChE in the basal forebrain neurons and the striatum because of their higher 
AChE activity. Via the AChE-inhibitory effect of donepezil in neuropharmacological 
experiments, a microdialysis technique has shown that the oral administration of donepezil 
leads to an increase in the level of ACh in the cerebral cortex of rats.
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It is well documented that the intra- and extracerebral blood vessels and capillaries are 
innervated not only with aminergic, but also with cholinergic nerve fibres, in both the human 
and the rat brain.68 The brain cortical blood flow is largely dependent on the normal function 
of cholinergic neurons located in the basal forebrain and projecting their axons to the cortex. 
A dysfunction of these cholinergic neurons or their axon terminals innervating the blood 
vessels may therefore lead to pathology of the cortical microcirculation.48 Indeed, a disturbed 
cerebral blood flow has been demonstrated in AD.63,74 The abnormalities may be dependent 
on cerebral endothelial cells, profound irregularities in the course of the vessels, thickening of 
the vascular basement membrane and a reduction or loss of innervations in the cerebral 
microvasculature. These factors may play significant roles in the dysfunction of the blood­
brain barrier, in the cerebral microcirculation and in the pathogenesis of AD.
Factors believed to stabilize or improve the blood circulation may result in an 
amelioration of the symptoms in AD.11 On the other hand, modulation of the cholinergic 
neurotransmission may result in changes in memory performance in AD patients.23 Indeed, if 
AChE inhibitors (e.g. donepezil) are used to reduce the AChE activity in the cholinergic 
nerves, it might be suspected that the ACh remaining in the cholinergic nerves innervating the 
intra- and extracerebral blood vessels may regulate the blood circulation in AD more 
effectively than without treatment. In our histochemical experiments, the AChE activity was 
inhibited by 2x10‘8 M donepezil, and totally abolished by 5x1 O’8 M donepezil. Application of 
this drug and/or other AChE inhibitors to ameliorate the blood circulation in the treatment of 
AD is therefore an important possibility.
Both human and animal in vivo studies have demonstrated a peripheral effect of 
donepezil. The oral administration of donepezil inhibited the pectoral muscle cholinesterase 
activity in young rat in a dose-dependent manner.39 Donepezil at or above 2.5 mg/kg caused 
fasciculation, a peripheral cholinergic sign of the activation of neuromuscular transmission.50 
In nerve-hemidiaphragm preparations, an intracellular recording technique revealed that the 
application of lxlO"9 M donepezil increased the amplitude, the time-to-peak and the half­
decay time of miniature end-plate potentials. In our in vitro experiments, the AChE activity in 
the NMJ was reduced by 2x1 O'8 M donepezil, suggesting a local effect of donepezil on the 
postsynaptic membrane of the NMJ. In human studies,8,67 muscle cramps were registered as a 
side-effect in patients receiving a high dose of donepezil (10 mg daily during a 24-week trial);
this could be attributed to the inhibition of AChE activity in the postsynaptic membrane 
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folding at the NMJ. When the effects of donepezil on the cholinergic structures in the CNS 
and PNS are compared, however, the drug is observed histochemically to be more selective 
for the brain cholinoceptive neuronal perikarya than for the neuromuscular junction. In the 
cortex, the AChE positivity in the pyramidal cells can be abolished by 2x1 O'8 M donepezil, 
while at the neuromuscular junction a similar level of inhibition can be achieved only with 
5x1 O'7 M. The results of this study reveal the importance of the regional, cellular and also 
tissue specificity of the effects of donepezil on AChE activity.34
7. SUMMARY AND CONCLUSIONS
7.1. Experiments in in vitro basal forebrain neuronal cultures:
1. We have provided the first identification of the cholinergic and cholinoceptive neurons
and their synaptic contacts in an in vitro basal forebrain neuronal culture system.
2. We have demonstrated that A01-42 and its fragments AP25-35 and AP31-35 are toxic
not only to cholinergic, but also to the cholinoceptive and GABAergic neurons.
3. Characteristic morphological changes have been revealed in the different transmitter­
containing neurons after Ap treatment:
a. ) The VAChT-immunoreactive neurons lost their processes after Ap treatment and
the cells become rounded.
b. ) In the AChE-positive cells, the intracellular localization of AChE was altered.
c. ) After Api-42 treatment, the enzyme was translocated either to the perikaryonal
plasma membrane or to a segment of the dendrite.
d. ) In GABAergic neurons, the processes were pruned and fragmented, and finally the
cells were rounded and lost their processes.
4. The VAChT-positive axon varicosities proved more sensitive than the SYN-
immunoreactive neuronal structures to Ap treatment.
Conclusion: The use of embryonic basal forebrain neuronal tissue cultures and their 
treatment with the neurotoxic Ap provides a good in vitro cellular model with which to 
investigate the effects of various chemical agents on the cholinergic neurons, and also to 
study the pathomechanism relating to AD.
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7.2. In vivo experiments on the axonal transport in the sciatic nerve of rat:
1. PS-1 is present in the axons and can be transported in both the anterograde and the 
retrograde direction in the motoric and sensory axons of the sciatic nerve of rat.
2. We have discovered that not only the C-terminal and N-terminal fragments of PS-1, but
also the holoprotein may be transported bidirectionally in the axons.
3. By means of Western blot studies, we have presented evidence that APP is conveyed 
bidirectionally and may carry information both from the cell body to the nerve terminal 
and from the axonal terminal to the neuronal perikarya.
4. It has been discovered that A0 can disturb the fast axonal transport of AChE, APP, VAChT
and SYN.
Conclusion: The in vivo neurotoxic effect of A01-42 on the axonal transport of various 
proteins has been demonstrated.
7.3. In vitro effect of donepezil in autopsy human and rat brain:
1. It has been demonstrated in in vitro experiments that donepezil (used for the treatment of
AD patients) exerts a dose-dependent inhibitory effect on AChE activity both in the 
autopsy human brain and in rat brain samples.
2. Donepezil selectively affects the different brain areas and, within these, the cholinoceptive
and cholinergic structures.
3. The most sensitive areas are the cortex and the hippocampal formation.
4. Within the different layers of the cortex, the cholinoceptive AChE-positive postsynaptic
pyramidal cell bodies proved more sensitive than the presynaptic cholinergic axonal 
processes.
5. The most resistant cholinergic fibres are present in the putamen, the basolateral nucleus of
the amygdala, the olfactory tubercle and the lateral habenular nucleus.
6. In the rat brain, the postsynaptic cholinoceptive and presynaptic cholinergic structures are
inhibited by nearly the same dose of donepezil as in the human brain.
7. Donepezil can not only affect the AChE activity in the CNS, but also exert an inhibitory
effect in the PNS tissue. It effectively inhibits the AChE activity at the NMJ and in the 
intra- and extracerebral blood vessel innervation.
Conclusion: Donepezil used for the treatment of AD individuals may inhibit the AChE 
activity not only in the brain, but also in the PNS tissue.
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